Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
17.69
+0.98 (5.90%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Travere Therapeutics Revenue
In the year 2024, Travere Therapeutics had annual revenue of $233.18M with 60.55% growth. Travere Therapeutics had revenue of $74.79M in the quarter ending December 31, 2024, with 65.98% growth.
Revenue (ttm)
$233.18M
Revenue Growth
+60.55%
P/S Ratio
5.65
Revenue / Employee
$605,649
Employees
385
Market Cap
1.57B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 233.18M | 87.94M | 60.55% |
Dec 31, 2023 | 145.24M | 35.78M | 32.69% |
Dec 31, 2022 | 109.46M | -22.38M | -16.97% |
Dec 31, 2021 | 131.84M | -66.49M | -33.52% |
Dec 31, 2020 | 198.32M | 22.98M | 13.11% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.90B |
TVTX News
- 13 days ago - Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 24 days ago - Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025 - Business Wire
- 5 weeks ago - Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGS - GlobeNewsWire
- 2 months ago - Travere Therapeutics to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Travere Therapeutics, Inc. (TVTX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - Travere Therapeutics to Submit sNDA for FILSPARI® (sparsentan) in FSGS - GlobeNewsWire